A retrospective efficacy and safety study of pembrolizumab/cetuximab neoadjuvant therapy in locally advanced hypopharyngeal cancer
The neoadjuvant TP regimen integrating pembrolizumab or cetuximab was associated with higher transoral surgery (TOS) rates and laryngeal preservation rates. Notably, the TP + PEMBRO regimen outperformed the TP + CETUX regimen in terms of treatment response rate and the proportion of minimally invasive surgeries, suggesting a novel and efficacious neoadjuvant treatment for LAHPC.
Authors
- Hanqing Lin (ORCID: https://orcid.org/0000-0003-3323-1828)
- Zhihong Chen (ORCID: https://orcid.org/0000-0002-7056-1335)
- Xiaobo Wu (ORCID: https://orcid.org/0000-0002-3238-0728)
- Chang Lin (ORCID: https://orcid.org/0000-0002-7153-6967)
- Gongbiao Lin (ORCID: https://orcid.org/0000-0002-9333-9868)
- Guangnan Yao (ORCID: https://orcid.org/0000-0001-9052-1966)
Institutions
- Fujian Medical University (CN)
- First Affiliated Hospital of Fujian Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-06-20
- DOI
- https://doi.org/10.3389/fimmu.2025.1574988
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00